Sign In
Buy BNTX
$90.58
-2.27 (-2.44%)
At Close: Jul 31, 2026
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
08:18am, Tuesday, 10'th Jun 2025
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
06:07pm, Monday, 09'th Jun 2025
Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
07:00am, Friday, 06'th Jun 2025
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327
Bristol Myers Collaborates With BNTX for Oncology Candidate
01:16pm, Tuesday, 03'rd Jun 2025
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
Bristol Myers CEO explains why he's spending billions on BioNTech deal
03:50pm, Monday, 02'nd Jun 2025
Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ann
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
02:51pm, Monday, 02'nd Jun 2025
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Why BioNTech Stock Soared Today
01:38pm, Monday, 02'nd Jun 2025
BioNTech (BNTX 20.19%), one of the companies made famous for its role developing vaccines with Pfizer (PFE -0.47%) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news entirely
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
12:22pm, Monday, 02'nd Jun 2025
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The comp
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
11:08am, Monday, 02'nd Jun 2025
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
08:46am, Monday, 02'nd Jun 2025
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
07:42am, Monday, 02'nd Jun 2025
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership
06:50am, Monday, 02'nd Jun 2025
U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , on an experimental cancer drug, in a deal that could eventually exceed $11 b
MAINZ, Germany, and PRINCETON, USA, June 2, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
08:15am, Tuesday, 27'th May 2025
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company's diversified onc
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
09:41am, Wednesday, 21'st May 2025
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
